Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry

被引：0
|
作者：
Michael Guger
Christian Enzinger
Fritz Leutmezer
Franziska Di Pauli
Jörg Kraus
Stefan Kalcher
Erich Kvas
Thomas Berger
机构：
[1] Kepler University Hospital GmbH,Clinic for Neurology 2, Med Campus III
[2] Johannes Kepler University Linz,Medical Faculty
[3] Medical University of Graz,Department of Neurology
[4] Medical University of Vienna,Department of Neurology
[5] Medical University of Innsbruck,Clinical Department of Neurology
[6] Paracelsus Medical University and Salzburger Landeskliniken,Department of Laboratory Medicine
[7] Heinrich-Heine-University,Department of Neurology, Medical Faculty
[8] Hermesoft,undefined
[9] Data management,undefined
[10] Hermesoft,undefined
[11] Statistics,undefined
来源：
Journal of Neurology | 2021年 / 268卷
关键词：
Disability progression; Long-term; Multiple sclerosis; Natalizumab; Predictor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4303 / 4310
页数：7
相关论文
共 50 条
  • [21] Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up
    Kaufmann, Maxi
    Haase, Rocco
    Proschmann, Undine
    Ziemssen, Tjalf
    Akguen, Kafja
    FRONTIERS IN NEUROLOGY, 2018, 9
  • [22] Inflammatory Activity on Natalizumab Predicts Short-Term but Not Long-Term Disability in Multiple Sclerosis
    Raffel, Joel
    Gafson, Arie R.
    Dandaleh, Samer
    Malik, Omar
    Jones, Brynmor
    Nicholas, Richard
    PLOS ONE, 2017, 12 (01):
  • [23] The long-term impact of natalizumab on multiple sclerosis: to continue or to stop?
    Sangalli, F.
    Moiola, L.
    Radaelli, M.
    Ferre, L.
    Esposito, F.
    Colombo, B.
    Martinelli, V.
    Comi, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 823 - 823
  • [24] EARLY PREDICTION OF LONG-TERM RESPONSE TO NATALIZUMAB IN MULTIPLE SCLEROSIS
    Raffel, Joel
    Gafson, Arie
    Dahdaleh, Samer
    Nicholas, Richard
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2015, 86 (11):
  • [25] The long-term impact of natalizumab on multiple sclerosis: to continue or to stop?
    Sangalli, F.
    Moiola, L.
    Radaelli, M.
    Esposito, F.
    Colombo, B.
    Rodegher, M.
    Martinelli-Boneschi, F.
    Martinelli, V.
    Comi, G.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 300 - 300
  • [26] Clinical predictors of long-term outcome in multiple sclerosis patients: a prospective cohort study
    Ivanovic, J.
    Martinovic, V.
    Mesaros, S.
    Pekmezovic, T.
    Drulovic, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 429 - 429
  • [27] Confirmed Progression independent of Relapse Activity in Multiple Sclerosis Patients under long-term Natalizumab Treatment.
    Graf, Jonas
    Leussink, Verena
    Soncin, Giulia
    Lepka, Klaudia
    Meinl, Ingrid
    Kumpfel, Tania
    Hartung, Hans-Peter
    Havla, Joachim
    Aktas, Orhan
    Albrecht, Philipp
    NEUROLOGY, 2020, 94 (15)
  • [28] Long-term outcome in patients with chronic progressive multiple sclerosis
    Kountouris, D
    JOURNAL OF NEUROLOGY, 2004, 251 : 63 - 63
  • [29] Serum Neurofilament-light and Contactin-1 Association with Long-term Brain Atrophy in Natalizumab-treated Multiple Sclerosis
    van Lierop, Z. Y.
    Noteboom, S.
    Schoonheim, M. M.
    Geurts, J. J.
    Uitdehaag, B. M.
    Teunissen, C. E.
    Martijn, S.
    Killestein, J.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 47 - 47
  • [30] Long-term efficacy and tolerability of natalizumab treatment in multiple sclerosis patients: a multicentre experience in Italy
    Totaro, R.
    Lugaresi, A.
    Bellantonio, P.
    Danni, M.
    Costantino, G.
    Gasperini, C.
    Florio, C.
    Pucci, E.
    Maddestra, M.
    Spitaleri, D.
    Lus, G.
    Ardito, B.
    Farina, D.
    Rossi, M.
    Carolei, A.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S215 - S216
12345